secwatch.observer — SEC 8-K summary
======================================

Issuer:     BICYCLE THERAPEUTICS PLC (BCYC)
CIK:        0001761612
Form:       8-K
Filed at:   2026-07-30T11:05:32+00:00
Accession:  0001104659-26-088455
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicycle Therapeutics Q2 net loss $50.3M ($0.72/share); cash $510.1M; clinical progress on nuzefatide and zelenectide
--------------------------------------------------------------------------------

- Net loss of $50.3M ($0.72 per share) for Q2 2026, compared to $79.0M ($1.14) in Q2 2025.
- Cash and equivalents of $510.1M as of June 30, 2026; expected cash runway into 2030.
- R&D expenses fell to $41.2M from $71.0M, driven by workforce reduction and lower zelenectide costs.
- First patient dosed in Phase 2 trial of nuzefatide in recurrent pancreatic cancer in April 2026.
- Expanded Clinical Advisory Board with Thomas Powles, MD, a leader in urothelial cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761612/000110465926088455/0001104659-26-088455-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761612/000110465926088455/tm2621593d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-088455

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer